当前位置:首页 - 行情中心 - 海尔生物(688139) - 财务分析 - 现金流量表

海尔生物

(688139)

  

流通市值:104.03亿  总市值:104.03亿
流通股本:3.18亿   总股本:3.18亿

现金流量表

报告期2024-12-312024-09-302024-06-302024-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金2,331,426,426.331,585,401,166.511,042,814,256.74538,911,911.05
收到的税费返还36,631,224.7522,367,268.4916,399,415.38,066,379.61
收到其他与经营活动有关的现金61,228,597.9346,861,396.4529,299,318.2713,339,628.99
经营活动现金流入的平衡项目0000
经营活动现金流入小计2,429,286,249.011,654,629,831.451,088,512,990.31560,317,919.65
购买商品、接受劳务支付的现金1,159,181,659.06840,997,402.69543,576,454.67209,203,122.35
支付给职工以及为职工支付的现金573,465,500.65419,820,522.81293,183,294.04155,023,576.2
支付的各项税费140,800,365.81108,520,079.2386,362,913.740,784,136.41
支付其他与经营活动有关的现金264,171,805.23171,324,375.38106,114,294.1478,102,087.87
经营活动现金流出的平衡项目0000
经营活动现金流出小计2,137,619,330.751,540,662,380.111,029,236,956.55483,112,922.83
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额291,666,918.26113,967,451.3459,276,033.7677,204,996.82
二、投资活动产生的现金流量:
收回投资收到的现金2,964,720,441.372,032,950,6721,287,600,000381,400,000
取得投资收益收到的现金16,107,763.4322,749,755.278,425,673.192,296,067.11
处置固定资产、无形资产和其他长期资产收回的现金净额819,713.89840,040710,040688,000
投资活动现金流入的平衡项目0000
投资活动现金流入小计2,981,647,918.692,056,540,467.271,296,735,713.19384,384,067.11
购建固定资产、无形资产和其他长期资产支付的现金126,704,812.7887,493,691.7766,789,740.8540,613,472.06
投资支付的现金3,485,754,0922,265,280,6721,079,793,870.68351,300,000
取得子公司及其他营业单位支付的现金160,405,720.83158,324,843.76148,053,356.18-
投资活动现金流出的平衡项目0000
投资活动现金流出小计3,772,864,625.612,511,099,207.531,294,636,967.71391,913,472.06
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-791,216,706.92-454,558,740.262,098,745.48-7,529,404.95
三、筹资活动产生的现金流量:
吸收投资收到的现金4,465,172.8550,000250,000170,000
其中:子公司吸收少数股东投资收到的现金4,465,172.8550,000250,000170,000
取得借款收到的现金10,000,00010,000,00010,000,0005,000,000
收到其他与筹资活动有关的现金179,520,750---
筹资活动现金流入平衡项目0000
筹资活动现金流入小计193,985,922.810,550,00010,250,0005,170,000
偿还债务支付的现金18,588,206.829,500,0007,500,000-
分配股利、利润或偿付利息支付的现金163,930,252.88164,576,248.67164,113,792.8954,541.68
其中:子公司支付给少数股东的股利、利润840,481.61---
支付其他与筹资活动有关的现金238,294,737.5456,454,457.7130,592,366.5425,611,566.75
筹资活动现金流出平衡项目0000
筹资活动现金流出小计420,813,197.24230,530,706.38202,206,159.4325,666,108.43
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-226,827,274.44-219,980,706.38-191,956,159.43-20,496,108.43
四、汇率变动对现金及现金等价物的影响4,434,529.58962,777.382,036,804.431,245,666.7
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-721,942,533.52-559,609,217.92-128,544,575.7650,425,150.14
加:期初现金及现金等价物余额1,256,646,564.21,256,646,564.21,256,646,564.21,256,646,564.2
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额534,704,030.68697,037,346.281,128,101,988.441,307,071,714.34
补充资料:
净利润381,008,045.8-239,137,127.93-
资产减值准备2,756,186.74-1,728,897.13-
固定资产和投资性房地产折旧70,389,400.37-35,227,195.01-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧69,620,755.37-34,842,872.51-
投资性房地产折旧768,645-384,322.5-
无形资产摊销45,738,498.63-21,910,106.95-
长期待摊费用摊销1,841,795.77-759,884.63-
递延收益摊销-7,696,411.04--2,328,838.52-
处置固定资产、无形资产和其他长期资产的损失-233,571.76-130,256.06-
固定资产报废损失1,864,142.84-8,520.52-
公允价值变动损失-5,468,787.54-1,139,396.68-
财务费用-12,156,302.68--15,766,287.56-
投资损失-23,794,761.37--11,307,110.66-
递延所得税-19,479,822.9--9,768,170.59-
其中:递延所得税资产减少-14,084,705.66--10,668,871.17-
递延所得税负债增加-5,395,117.24-900,700.58-
存货的减少-68,722,067.41-20,424,490.33-
经营性应收项目的减少-173,735,221.4--201,218,521.38-
经营性应付项目的增加76,510,475.64--41,372,396.3-
其他--3,069,941.42-
现金的期末余额534,704,030.68-1,128,101,988.44-
减:现金的期初余额1,256,646,564.2-1,256,646,564.2-
公告日期2025-03-292024-10-302024-08-232024-04-26
审计意见(境内)标准无保留意见
TOP↑